5
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T1621 | Imatinib Mesylate | ST-1571 Mesylate,STI-571,CGP-57148B | Bcr-Abl , PDGFR , c-Kit , Autophagy |
Imatinib Mesylate (STI-571) is a tyrosine kinase receptor inhibitor with antineoplastic activity (IC50s: 0.6 μM, 0.1 μM and 0.1 μM for v-Abl, c-Kit and PDGFR, respectively). | |||
T22859 | Imatinib hydrochloride | Others | |
Imatinib is a multi-target inhibitor of v-Abl, c-Kit, and PDGFR (IC50: 0.6 μM, 0.1 μM, and 0.1 μM, respectively). Imatinib is used to treat chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs), and... | |||
T11640 | Imatinib-d8 | CGP-57148B D8,STI571 D8 | Others |
Imatinib D8 is a deuterium-labeled Imatinib. Imatinib is an orally bioavailable tyrosine kinases inhibitor that inhibits BCR/ABL, PDGFR, v-Abl, and c-kit kinase activity. | |||
T11639 | Imatinib D4 | CGP-57148B D4,STI571 D4 | Others |
Imatinib D4 is a deuterium-labeled Imatinib. Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, PDGFR, v-Abl, and c-kit kinase activity. | |||
T6230 | Imatinib | STI571,CGP057148B,ST-1571 | SARS-CoV , Bcr-Abl , PDGFR , c-Kit , Autophagy |
Imatinib (STI571) is a multi-targeted receptor tyrosine kinase inhibitor that selectively inhibits the kinase activities of BCR/ABL, v-Abl, PDGFR, and c-kit with oral activity. Imatinib has antitumor activity for the tre... |